SciSparc announces enrollment of first patient in trial for children with ASD

SciSparc announced that the first patient has been enrolled in the Company’s clinical trial assessing the efficacy and safety of SCI-210 for the treatment of children with autism spectrum disorder between the ages of 5 and 18. Autism, also referred to as autism spectrum disorder, is one of the most common developmental disabilities globally with a prevalence of approximately one in 36 children, according to estimates from the Centers for Disease Control and Prevention’s Autism and Developmental Disabilities Monitoring Network and is accompanied by an unmet need for efficient and safe treatments. The Company’s goal is to sell SCI-210 first in Israel and then in other countries, subject to obtaining the requisite regulatory approvals.